| Title | Author(s) | Year | View Count |
 | Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications | Zhou, XJ; Lim, SG; Lloyd, DM; Chao, GC; Brown, NA; Lai, CL | 2006 | 236 |
 | Final Results of a Phase I/II Dose Escalation Trial of Valtorcitabine in Patients with Chronic Hepatitis B | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lloyd, D; Pietropalolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 130 |
| Crystal structure and luminescence of lanthanide monodentate complexes [Ln(C4N4H6O)2(H2O)6]Cl3 and [Ln(C4N4H6O)2(H2O)3(NO3)3](Ln=Tb or Eu) | Law, GL; Wong, KL; Zhou, XJ; Wong, WT; Tanner, PA | 2005 | 149 |
| Final results of a phase I/II dose escalation trial of valtorcitabine in patients with chronic hepatitis B. | Lim, SG; Lai, CL; Myers, M; Yuen, RMF; Wai, CT; Lyoyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Brown, NA | 2005 | 114 |
 | A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection | Lai, CL; Lim, SG; Brown, NA; Zhou, XJ; Lloyd, DM; Lee, YM; Yuen, MF; Chao, GC; Myers, MW | 2004 | 115 |
| Valtorcitabine provides potent suppression of hepatitis B virus in patients with chronic hepatitis B: Results of a phase I/II clinical trial. | Lai, CL; Brown, NA; Yuen, RMF; Wai, CT; Lloyd, D; Pietropaolo, K; Zhou, XJ; Chao, G; Lim, SG | 2004 | 173 |
| The biological behaviour of human adenoid cystic carcinoma cells transduced with interleukin-2-gene | Sun, CX; He, RG; Cheung, LK; Zhang, ZY; Chen, WT; Liu, XK; Zhou, XJ; Tang, ZY; Chen, SS | 2002 | 102 |
|
